Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
NCT ID: NCT01166230
Last Updated: 2019-04-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
551 participants
OBSERVATIONAL
2010-06-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
NCT00233402
A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
NCT00412971
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
NCT01551407
Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer
NCT00052637
Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice
NCT02012036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will also lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.
No safety data was collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Ta/T1, randomized to white light cystoscopy
Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
No interventions assigned to this group
Patients with Ta/T1 randomized to Hexvix cystoscopy
Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Photocure
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Herbert Barton Grossman, MD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas MD Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Cancer Center, Department of Urology
Stanford, California, United States
V.A. Medical Center
Gainesville, Florida, United States
University of Miami School of Medicine
Miami, Florida, United States
South Florida Clinical Research Center, Inc.
Pembroke Pines, Florida, United States
The Emory Clinic, Dept of Urology
Atlanta, Georgia, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Urologic Clinical Research Unit, Gonda 7102, Mayo Clinic Rochester
Rochester, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Mount Sinai Medical Center, Department of Urology
New York, New York, United States
URMC
Rochester, New York, United States
Thomas Jefferson Medical College, Department of Neurology
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center, Department of Urologic Surgery
Nashville, Tennessee, United States
Baylor College of Medicine, Scott Department of Urology
Houston, Texas, United States
The University of Texas MD Anderson cancer center
Houston, Texas, United States
AKH, Klinik für Urologie der Universität Wien
Vienna, , Austria
Kingston General Hospital
Kingston, Ontario, Canada
CHUQ Hotel-Dieu de Quebec
Québec, , Canada
University Clinic of Giessen, Department of Urology
Giessen, , Germany
Klinikum der Universität München-Großhardern, Urologische Klinik und Poliklinik
München, , Germany
Urologische Klinik München-Planegg
Planegg, , Germany
Akadem. Lehrkrankenhaus der Uni Regensburg, Klinik für Urologie
Regensburg, , Germany
Universitätsklinik Tuebingen, Universitätsklinik für Urologie
Tübingen, , Germany
Department of Urology, Academic Medical Center, University of Amsterdam
Amsterdam, , Netherlands
Department of Urology, UMC St. Radboud
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Bladder Cancer Advocacy Network (BCAN)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PC B305/E10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.